Bristol-Meyers Squibb participated in the $78.5m round, which will be used to push Silverback Therapeutics' lead cancer drug candidate towards clinical trials.
US-based biologic drug developer Silverback Therapeutics completed a $78.5m series B round yesterday featuring pharmaceutical firm Bristol-Meyers Squibb and life sciences real estate investment trust Alexandria Real Estate Equities (AREE).
The round was led by venture capital firm US Venture Partners (USVP) and included Nextech Invest, Hunt Investment Group, Pontifax Venture Capital, OrbiMed, Colt Ventures and NS Investment. AREE took part through its Alexandria Venture Investments vehicle.
Silverback’s lead drug candidate is SBT6050, an antibody it is developing to fight…
